Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 12:48 PM ET


Company Overview of Galleon Pharmaceuticals, Inc.

Company Overview

Galleon Pharmaceuticals, Inc. discovers and develops potential drugs for the treatment of breathing-control conditions associated with surgical anesthesia, drug-induced respiratory depression, pain management, and sleep apnea. It focuses on respiratory depression in the acute care market and sleep apnea in the chronic care market; and ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.

213 Witmer Road

Horsham, PA 19044

United States

Founded in 2003





Key Executives for Galleon Pharmaceuticals, Inc.

Chief Executive Officer
Age: 47
Founder and Strategic Advisor
Managing Partner of Morgenthaler Ventures
Age: 77
Chief Technology Officer and Vice President of Chemistry
Head of Bioanalytical Chemistry & DMPK
Compensation as of Fiscal Year 2015.

Galleon Pharmaceuticals, Inc. Key Developments

Galleon Pharmaceuticals Names Joseph Oliveto as Chief Executive Officer

Galleon Pharmaceuticals announced that it has named Joseph Oliveto as Chief Executive Officer, effective immediately. Mr. Oliveto replaces James C. Mannion, Ph.D., who will retire as CEO and continue to serve as a strategic advisor to the company. Mr. Oliveto brings more than 25 years of pharmaceutical and biotech experience across the areas of drug development, commercialization, manufacturing and business development. Most recently, Mr. Oliveto served as President and CEO of Chelsea Therapeutics, a publicly held biopharmaceutical company. During his tenure as CEO, he led the company through the FDA’s approval of Northera™ for the treatment of neurogenic orthostatic hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc.

Galleon Pharmaceuticals Announces Publication of Proof-of- Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic

Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology. The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study's pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug's safety and efficacy. GAL-021 is being developed to prevent respiratory complications in surgical patients, including those at higher risk due to sleep apnea. According to a recent report in the New England Journal of Medicine, 25% to 80% of surgical patients have sleep apnea predisposing them to the rapidly emerging perioperative sleep apnea epidemic. The combination of sleep apnea with respiratory depressant drugs such as opioids, sedatives and anesthetics is especially dangerous and complicates care of these patients.

Similar Private Companies By Industry

Company Name Region
Milkhaus Laboratory, Inc. United States
Symmetrix Pharmaceuticals, LLC United States
Sigma Global Corporation United States
NSA International, Inc. United States
Peloton Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galleon Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at